Evidence map›Paper›PMID 26828465›Full record

ArticleVirology2016

3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.

Reed F Johnson, Ulas Bagci, Lauren Keith, Xianchun Tang, Daniel J Mollura, Larry Zeitlin, Jing Qin, Louis Huzella, Christopher J Bartos, Natasha Bohorova and 19 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Low level CORespiratory physiology & neurobiology · 2024
    Article
  6. Longitudinal analyses usingAntiviral research · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Human coronaviruses and therapeutic drug discovery.Infectious diseases of poverty · 2021
    Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 7 institutions in 1 country.

Reed F JohnsonEmerging Viral Pathogens Section National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA. Electronic address: johnsonreed@mail.nih.gov.
Ulas BagciCenter for Infectious Disease Imaging, National Institutes of Health Clinical Center, Bethesda MD 20892, USA; Center for Research in Computer Vision (CRCV), Department of Electrics Electronics and Computer Science, University of Central Florida, Orlando, FL 32816, USA.
Lauren KeithIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Xianchun TangDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Daniel J MolluraCenter for Infectious Disease Imaging, National Institutes of Health Clinical Center, Bethesda MD 20892, USA.
Larry ZeitlinMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Jing QinBiostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Louis HuzellaIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Christopher J BartosIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Natasha BohorovaMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Ognian BohorovMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Charles GoodmanMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Do H KimMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Michael H PaultyMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Jesus VelascoMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Kevin J WhaleyMapp Biopharmaceutical, Inc., San Diego CA 92121, USA.
Joshua C JohnsonIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
James PettittIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Britini L OrkIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Jeffrey SolomonClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research,Frederick, MD 21702-USA.
Nicholas OberlanderIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Quan ZhuDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Jiusong SunDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
Michael R HolbrookIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Gene G OlingerIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Ralph S BaricDepartment of Microbiology and Immunology, Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Lisa E HensleyIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Peter B JahrlingEmerging Viral Pathogens Section National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD 21702, USA.
Wayne A MarascoDepartment of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
National Institutes of Health · USHarvard University · USLeidos (United States) · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health Clinical Center · USUniversity of Central Florida · USUniversity of North Carolina at Chapel Hill · US

Funding

Integrated Research Facility at Fort DetrickZIDAI009006 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI COE, LINDA · 2009 to 2018
$341.7M
Pathogenesis and countermeasures of poxviruses, hemorrhagic fever viruses, MERSZIAAI001025 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI JOHNSON, REED · 2009 to 2018
$14.1M
Broad Spectrum Neutralizing Human Abs to SARS and Related CoronavirusesR01AI085524 · NIAID · DANA-FARBER CANCER INST · PI MARASCO, WAYNE A. · 2010 to 2014
$5.4M
Computer-Aided Detection for Infectious Disease ImagingZIACL090018 · CLC · CLINICAL CENTER · PI MOLLURA, DANIEL · 2010 to 2018
$0k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 AI999999Intramural NIH HHS ZIA AI001025NCI NIH HHS HHSN261200800001ENIAID NIH HHS HHSN272200700016INIAID NIH HHS R01 AI085524NIAID NIH HHS R01AI085524
6 · The paper itself

Abstract

Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in 2012 as the causative agent of a severe, lethal respiratory disease occurring across several countries in the Middle East. To date there have been over 1600 laboratory confirmed cases of MERS-CoV in 26 countries with a case fatality rate of 36%. Given the endemic region, it is possible that MERS-CoV could spread during the annual Hajj pilgrimage, necessitating countermeasure development. In this report, we describe the clinical and radiographic changes of rhesus monkeys following infection with 5×10(6) PFU MERS-CoV Jordan-n3/2012. Two groups of NHPs were treated with either a human anti-MERS monoclonal antibody 3B11-N or E410-N, an anti-HIV antibody. MERS-CoV Jordan-n3/2012 infection resulted in quantifiable changes by computed tomography, but limited other clinical signs of disease. 3B11-N treated subjects developed significantly reduced lung pathology when compared to infected, untreated subjects, indicating that this antibody may be a suitable MERS-CoV treatment.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, ViralCoronavirus InfectionsDisease Models, AnimalHumansLungMacaca mulattaMaleMiddle East Respiratory Syndrome CoronavirusAntibodies, MonoclonalAntibodies, ViralAnimal model, MERSAntibody therapyHuman monoclonal antibody therapyMERS-CoVRespiratory syndrome

Identifiers

PMID26828465
PMCPMC4769911
OpenAlexW2283863277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.